- Home
- ALT vs HUMA Comparison
ALT vs HUMA Comparison
Compare ALT & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALT
- HUMA
- Stock Information
- Founded
- ALT 1997
- HUMA 2004
- Country
- ALT United States
- HUMA United States
- Employees
- ALT N/A
- HUMA N/A
- Industry
- ALT Biotechnology: Pharmaceutical Preparations
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- ALT Health Care
- HUMA Health Care
- Exchange
- ALT Nasdaq
- HUMA Nasdaq
- Market Cap
- ALT 529.9M
- HUMA 577.7M
- IPO Year
- ALT N/A
- HUMA N/A
- Fundamental
- Price
- ALT $6.83
- HUMA $4.56
- Analyst Decision
- ALT Strong Buy
- HUMA Strong Buy
- Analyst Count
- ALT 8
- HUMA 7
- Target Price
- ALT $19.71
- HUMA $13.43
- AVG Volume (30 Days)
- ALT 2.5M
- HUMA 8.3M
- Earning Date
- ALT 11-12-2024
- HUMA 11-08-2024
- Dividend Yield
- ALT N/A
- HUMA N/A
- EPS Growth
- ALT N/A
- HUMA N/A
- EPS
- ALT N/A
- HUMA N/A
- Revenue
- ALT $52,000.00
- HUMA N/A
- Revenue This Year
- ALT N/A
- HUMA N/A
- Revenue Next Year
- ALT N/A
- HUMA $5,584.53
- P/E Ratio
- ALT N/A
- HUMA N/A
- Revenue Growth
- ALT N/A
- HUMA N/A
- 52 Week Low
- ALT $5.28
- HUMA $2.80
- 52 Week High
- ALT $14.84
- HUMA $9.97
- Technical
- Relative Strength Index (RSI)
- ALT 41.57
- HUMA 49.10
- Support Level
- ALT $6.19
- HUMA $4.30
- Resistance Level
- ALT $7.83
- HUMA $4.67
- Average True Range (ATR)
- ALT 0.39
- HUMA 0.37
- MACD
- ALT -0.04
- HUMA -0.04
- Stochastic Oscillator
- ALT 39.02
- HUMA 36.99
About ALT Altimmune Inc.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.